David R. Lally, MD

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the utility of a novel port delivery system for the delivery of anti-VEGF treatment.

Thought leaders review the clinical and practical implications of a novel port delivery system for the treatment of neovascular age-related macular degeneration [AMD].

Michael A. Klufas, MD, reviews the design and key findings from clinical trials for faricimab.

Carl D. Regillo, MD, FACS; and David R. Lally, MD, discuss the recent FDA approval of faricimab and the potential impact of having a molecule that inhibits 2 pathways that play a role in diabetic macular edema and neovascularization in the treatment armamentarium.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the implications of real-world evidence indicating fewer visual gains associated with anti-VEGF therapies compared with clinical trials.

Dr Regillo leads a discussion with retina specialists about the utility and limitations of anti-VEGF agents in the treatment of patients with AMD and DME.

Dr Regillo, Dr Cooper, and Dr Klufas emphasize the importance of a personalized approach and share strategies for assessing outcomes in patients with AMD and DME.

A panel of retina specialists discuss how to balance durability, visual acuity, and other factors when selecting the appropriate regimen for patients with AMD and DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, share guidance on how to initiate conversations with patients who have been diagnosed with AMD or DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, review the clinical benefits of early detection of AMD and DME.

Carl D. Regillo, MD, FACS; Michael A. Klufas, MD; and David R. Lally, MD, discuss how increasing awareness regarding AMD and DME among patients and the medical community may lead to early treatment interventions.